Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 11/20 | 0.59 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | SCN4A | P35499 | 7/20 | 0.50 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.48 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.48 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7964814 | 0.83 | IDO1 (0.52) | TACR1IDO1 | |
| SCHEMBL7964819 | 0.83 | IDO1 (0.52) | TACR1IDO1 | |
| SCHEMBL4981770 | 0.79 | TACR1 (0.59) | TACR1SCN4ACACNA1FCACNA1DCACNA1S | |
| SCHEMBL25183077 | 0.79 | SLC1A5 (0.53) | IDO1 | |
| SCHEMBL25183076 | 0.79 | SLC1A5 (0.53) | IDO1 | |
| SCHEMBL3282691 | 0.78 | PNMT (0.48) | IDO1SCN4A | |
| SCHEMBL7312106 | 0.78 | IDO1 (0.50) | IDO1 | |
| Hydrochloric Acid SCHEMBL7312436 | 0.77 | IDO1 (0.51) | IDO1 | |
| SCHEMBL3774965 | 0.77 | IDO1 (0.67) | IDO1 | |
| SCHEMBL2782707 | 0.77 | SCN4A (0.68) | TACR1SCN4ACACNA1FCACNA1DCACNA1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393958-B2 | Triamide-substituted heterobicyclic compounds | PFIZER, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | TACR1 814/4885IDO1 3133/4885SCN4A 3286/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | TACR1 814/4885IDO1 3133/4885SCN4A 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.